2023
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2019
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation 2019, 139: 2285-2288. PMID: 30955360, DOI: 10.1161/circulationaha.118.039331.Peer-Reviewed Original ResearchDeath: The Simple Clinical Trial Endpoint.
Eisenstein EL, Prather K, Greene SJ, Harding T, Harrington A, Gabriel D, Jones I, Mentz RJ, Velazquez EJ, Anstrom KJ. Death: The Simple Clinical Trial Endpoint. 2019, 257: 86-91. PMID: 30741178, PMCID: PMC8228236.Peer-Reviewed Original Research
2018
HFrEF other treatment: revascularization
Velazquez E, Petrie M. HFrEF other treatment: revascularization. 2018, 1881-1884. DOI: 10.1093/med/9780198784906.003.0431.Peer-Reviewed Original Research
2017
Value of Cardiovascular Magnetic Resonance Imaging–Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial
Pai RG, Varadarajan P, Rouleau JL, Stebbins AL, Velazquez EJ, Al-Khalidi HR, Pohost GM. Value of Cardiovascular Magnetic Resonance Imaging–Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. JAMA Cardiology 2017, 2: 577-579. PMID: 28199489, PMCID: PMC5814980, DOI: 10.1001/jamacardio.2016.5492.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac Surgical ProceduresCardiomyopathiesFemaleHeart FailureHeart VentriclesHumansKaplan-Meier EstimateMagnetic Resonance ImagingMagnetic Resonance Imaging, CineMaleMiddle AgedMortalityMultivariate AnalysisMyocardial IschemiaOrgan SizePlastic Surgery ProceduresRisk AssessmentStroke VolumeConceptsIschemic Heart Failure (STICH) trialCardiovascular magnetic resonance imagingHeart Failure TrialVentricular ejection fractionPrecise risk stratificationMagnetic resonance imagingEjection fractionIschemic cardiomyopathySurgical treatmentFailure TrialRisk stratificationResonance imagingPatientsCardiomyopathyBaselineTrials
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailureComparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiureticsTorsemide Versus Furosemide in Heart Failure Patients
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O'Connor C, Velazquez EJ. Torsemide Versus Furosemide in Heart Failure Patients. Journal Of Cardiovascular Pharmacology 2015, 65: 438-443. PMID: 25945862, PMCID: PMC4423558, DOI: 10.1097/fjc.0000000000000212.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedComorbidityDatabases, FactualFemaleFurosemideHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedNorth CarolinaRetrospective StudiesRisk FactorsSex FactorsSodium Potassium Chloride Symporter InhibitorsSulfonamidesTertiary Care CentersTorsemideTreatment OutcomeUltrasonographyConceptsHeart failure patientsFailure patientsEffects of torsemideFurosemide-treated patientsMore comorbiditiesCause mortalityBaseline characteristicsProspective trialHeart failureLoop diureticsResidual confoundingPatientsDuke HospitalFurosemideRisk adjustmentTorsemideMortalityLab databaseComorbiditiesDiureticsHospitalTrials
2014
Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure)
Stewart RA, Szalewska D, She L, Lee KL, Drazner MH, Lubiszewska B, Kosevic D, Ruengsakulrach P, Nicolau JC, Coutu B, Choudhary SK, Mark DB, Cleland JG, Piña IL, Velazquez EJ, Rynkiewicz A, White H. Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure). JACC Heart Failure 2014, 2: 335-343. PMID: 25023813, PMCID: PMC4127151, DOI: 10.1016/j.jchf.2014.02.009.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryIschemic left ventricular dysfunctionLeft ventricular dysfunctionArtery bypass graft surgeryBypass graft surgeryPoor exercise capacityExercise capacityMedical therapyVentricular dysfunctionSTICH trialGraft surgeryBetter exercise capacityWalk testMedical managementPrognostic significanceTreatment allocationPhysical activityPatientsEarly riskHigh mortalityMortalityTherapyDysfunctionSurgeryTrials
2011
Response to Letter Regarding Article, “Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both”
Pouleur A, Barkoudah E, Uno H, Skali H, Finn P, Zelenkofske S, Belenkov Y, Mareev V, Velazquez E, Rouleau J, Maggioni A, Køber L, Califf R, McMurray J, Pfeffer M, Solomon S. Response to Letter Regarding Article, “Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both”. Circulation 2011, 123: e586-e587. DOI: 10.1161/circulationaha.111.021600.Commentaries, Editorials and LettersNo Mortality Benefit from CABG When Added to Optimal Medical Therapy in Patients with CAD and LV Dysfunction: Results from the STICH Trial
Velazquez E. No Mortality Benefit from CABG When Added to Optimal Medical Therapy in Patients with CAD and LV Dysfunction: Results from the STICH Trial. MD Conference Express 2011, 11: 20-21. DOI: 10.1177/155989771103012.Peer-Reviewed Original ResearchMyocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA. Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. New England Journal Of Medicine 2011, 364: 1617-1625. PMID: 21463153, PMCID: PMC3290901, DOI: 10.1056/nejmoa1100358.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular DiseasesCombined Modality TherapyCoronary Artery BypassCoronary Artery DiseaseEchocardiography, StressFemaleFollow-Up StudiesHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial IschemiaMyocardiumProportional Hazards ModelsStatistics, NonparametricTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftConceptsCoronary artery diseaseVentricular dysfunctionMedical therapyMyocardial viabilityArtery diseaseViable myocardiumSurvival benefitBaseline variablesIschemic left ventricular dysfunctionDifferential survival benefitSubstudy of patientsCoronary artery bypassLeft ventricular dysfunctionDobutamine echocardiographyUnderwent assessmentPatientsCABGDysfunctionTreatment assignmentTherapyMyocardiumDiseaseGreater likelihoodMortalityTrials
2010
Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve
Taekman J, Stafford-Smith M, Velazquez E, Wright M, Phillips-Bute B, Pfeffer M, Sellers M, Pieper K, Newman M, Van de Werf F, Diaz R, Leimberger J, Califf R. Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve. BMJ Quality & Safety 2010, 19: 405. PMID: 20702441, PMCID: PMC3258507, DOI: 10.1136/qshc.2008.028605.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionClinical trial researchLearning curvePatient rankMulticentre trialSlow enrollmentAcademic research organizationsPatient deathClinical trialsPatientsTrial conductTrial researchClinical researchPatient safetyPatient ordersTrialsInfarctionValsartanFirst yearDeathRecruitment ratesSimilar patternStart dateSafetySTICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment
Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JL. STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment. Journal Of The American College Of Cardiology 2010, 56: 490-498. PMID: 20670760, PMCID: PMC3259709, DOI: 10.1016/j.jacc.2009.11.102.Peer-Reviewed Original ResearchConceptsLow-risk patientsSTICH trialRAR groupBaseline characteristicsCardiac surgeryIschemic cardiomyopathyHigh-risk patientsNumber of patientsCountry of enrollmentSTICH patientsDuke DatabankRandomization groupTrial enrollmentCardiovascular diseaseRisk differencePatientsClinical decisionTrialsSurgeryCardiomyopathyRiskBroader populationEnrollment performanceDeathThirty-secondAtrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010, 96: 838. PMID: 20406769, DOI: 10.1136/hrt.2009.180182.Peer-Reviewed Original ResearchConceptsRhythm control strategyAcute Myocardial Infarction trialMyocardial Infarction trialAtrial fibrillationMyocardial infarctionRate control strategyEarly mortalityAnti-arrhythmic drug therapyTreatment of AFPeri-infarct periodIncidence of strokeManagement of patientsRisk of deathLate mortalityPatient populationDrug therapyCox modelPatientsMortalityInfarctionStrokeValsartanTrialsDeathDays
2007
Exceptional early blood pressure control rates: The ACCOMPLISH trial
Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M, Jamerson K, Bakris G, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen S, Cushman W, Papademetriou V, Weber M. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Pressure 2007, 16: 80-86. PMID: 17612905, DOI: 10.1080/08037050701395571.Peer-Reviewed Original ResearchConceptsBP control ratesControl rateCombination therapyHigh-risk hypertensionMean BP changeMulti-national trialStage 2 hypertensionAnti-hypertensive medicationsBlood pressure controlACCOMPLISH trialMaximal medicationHypertension trialsMean BPRenal diseaseInitial treatmentBP changesHypotensive eventsCurrent guidelinesPressure controlHypertensionOverall trialPatientsTherapyTrialsAnalysis of variance
2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trialThe first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension
JAMERSON K, BAKRIS G, WUN C, DAHLOF B, LEFKOWITZ M, MANFREDA S, PITT B, VELAZQUEZ E, WEBER M. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trialThe first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. American Journal Of Hypertension 2004, 17: 793-801. DOI: 10.1016/s0895-7061(04)00840-4.Peer-Reviewed Original Research
2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau J, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM, Investigators F. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal Of Heart Failure 2003, 5: 537-544. PMID: 12921816, DOI: 10.1016/s1388-9842(03)00112-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin Receptor AntagonistsCaptoprilDouble-Blind MethodFemaleGlyceraldehyde-3-Phosphate DehydrogenasesHeart FailureHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPeptide FragmentsRandomized Controlled Trials as TopicTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsAcute Myocardial Infarction trialAngiotensin receptor blockadeMyocardial Infarction trialHeart failureMyocardial infarctionACEI trialsRenin-angiotensin system blockadePlacebo-controlled trialVentricular systolic dysfunctionActive-controlled trialEvidence-based careHigh-risk populationEvidence-based therapiesCardiovascular outcomesSystem blockadeSystolic dysfunctionBaseline characteristicsStandard treatmentRepresentative cohortPatientsMI trialsTrialsValsartanACEIsLVSD